Scientific Workflow Scheduling for Cloud Computing Environments

The scheduling of workflow applications consists of assigning their tasks to computer resources to fulfill a final goal such as minimizing total workflow execution time. For this reason, workflow scheduling plays a crucial role in efficiently running experiments. Workflows often have many discrete tasks and the number of different task distributions possible and consequent time required to evaluate each configuration quickly becomes prohibitively large. A proper solution to the scheduling problem requires the analysis of tasks and resources, production of an accurate environment model and, most importantly, the adaptation of optimization techniques. This study is a major step toward solving the scheduling problem by not only addressing these issues but also optimizing the runtime and reducing monetary cost, two of the most important variables. This study proposes three scheduling algorithms capable of answering key issues to solve the scheduling problem. Firstly, it unveils BaRRS, a scheduling solution that exploits parallelism and optimizes runtime and monetary cost. Secondly, it proposes GA-ETI, a scheduler capable of returning the number of resources that a given workflow requires for execution. Finally, it describes PSO-DS, a scheduler based on particle swarm optimization to efficiently schedule large workflows. To test the algorithms, five well-known benchmarks are selected that represent different scientific applications. The experiments found the novel algorithms solutions substantially improve efficiency, reducing makespan by 11% to 78%. The proposed frameworks open a path for building a complete system that encompasses the capabilities of a workflow manager, scheduler, and a cloud resource broker in order to offer scientists a single tool to run computationally intensive applications

Propuesta estructural para edificación en Haití

(SPA)Se presenta en este artículo, el diseño estructural propuesto y ejecutado en un colegio situado en Puerto Príncipe, capital de Haití, en el que las solicitaciones extremas de viento y sismo típicas de este y otros muchos países subdesarrollados son determinantes. Este colegio se diseñó y construyó en fecha posterior al severo terremoto sufrido por Haití el 12 de enero de 2010. El esquema estructural propuesto resiste de forma óptima estas solicitaciones y se ajusta a su vez a los materiales, mano de obra y presupuestos propios de este tipo de países. El esquema estructural resiste las fuerzas sísmicas mediante pantallas de rigidización, usando para ello y esta es la mayor aportación de este artículo, los propios cerramientos, construidos mediante bloques de hormigón perforados, elementos baratos y comunes en Haití. El sistema es extrapolable a cualquier tipo de edificación, de ahí también el interés que esta propuesta puede tener también, por ejemplo, en viviendas sociales. (ENG)This article proposes a structural design of a building of public nature, in order that it resists the extreme typical solicitations of wind and earthquake of many underdeveloped countries, using the materials from thiese places. The proposed building is a school placed in Port-au-Prince, the capital of Haiti, which as we can remenber, suffered a big earthquake on January 10, 2010. A ideal structural system is proposed againts seismic forces with rigiditation cores using the enclosures with blocks of perforated concrete, cheap and common elements in Haiti

Revista Temas Agrarios Volumen 26; Suplemento 1 de 2021

1st International and 2nd National Symposium of Agronomic Sciences: The rebirth of the scientific discussion space for the Colombian Agro.1 Simposio Intenacional y 2 Nacional de Ciencias Agronómicas: El renacer del espacio de discusión científica para el Agro colombiano

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols

Animal Models of Alzheimer's Disease

© 2017 Elsevier Inc. All rights reserved. Alzheimer's disease is a major and increasing burden on families, communities, and national health budgets. Despite intensive and extended research there is still widespread debate about its cause(s) and no effective treatments exist. Familial (inherited, mainly early onset) and sporadic (mainly late onset) forms of the disease exist and it is uncertain to what extent they are related. Transgenic mouse models have dominated the investigation of this disease but their validity can be questioned. Numerous alternative models exist that can provide valuable information on the molecular and cellular basis of Alzheimer's disease. In this chapter we review the various invertebrate, nonmammalian vertebrate, and mammalian models and how these have been used to investigate this disease. We examine the strengths and weaknesses of these various model systems. Of course, animal models never completely reflect the true nature of a human disease but progress in understanding and finding preventative and ameliorative treatments for Alzheimer's disease is hindered by the lack of a convincing hypothesis for the cause of this complex condition

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field